Experience of use of the combined medication Vagiferon® for topical application in the treatment of bacterial vaginosis
- Authors: Metelkina S.A.1, Averina D.M.1, Kuptsova L.V.1, Guryev D.L.1
-
Affiliations:
- Regional Perinatal Center
- Issue: Vol 64, No 4 (2015)
- Pages: 95-98
- Section: Articles
- URL: https://journals.rcsi.science/jowd/article/view/1233
- DOI: https://doi.org/10.17816/JOWD64495-98
- ID: 1233
Cite item
Full Text
Abstract
Objective: To assess the efficacy of the combined medication Vagiferon® for topical application, containing antimicrobial, antifungal, antiviral and immunomodulatory components in the treatment of non-pregnant women with bacterial vaginosis. Study design: This paper presents the experience of use of the medication Vagiferon® in the treatment of 29 non-pregnant women aged 22-45 with bacterial vaginosis. The medication Vagiferon® was administered vaginally as 1 suppository 1 time per day at bedtime for 10 days. The patients underwent a standard pelvic exam, which included the study of their vaginal microflora content by the microscopic method (Gram staining). The study was undertaken before therapy, in 14 days after its start, and in three months after its completion. Results: According to our observations of patients with bacterial vaginosis, in 93,1 percent of cases complete clinical remission was noted. Microbiological efficacy of the treatment was 86,2 percent. The signs of disease recurrence as well as any side effects or rejection of the use of the medication were not registered. Conclusion: Based on the combination of high efficacy and safety of Vagiferon®, this medicine can be recommended for wide use in the gynaecological practice.
Full Text
##article.viewOnOriginalSite##About the authors
Svetlana Alexandrovna Metelkina
Regional Perinatal Centerhead of consultative and diagnostic department
Daria Michailovna Averina
Regional Perinatal Centerobstetrician-gynecologist, consultative and diagnostic department
Larisa Vyacheslavovna Kuptsova
Regional Perinatal CenterHead of clinical and diagnostic laboratory
Dmitry L’vovich Guryev
Regional Perinatal Center
Email: d_guriev@mail.ru
PhD, chief physician
References
- Ефимов Б. А., Тютюнник В. Л. Бактериальный вагиноз: современный взгляд на проблему. РМЖ. 2008; 16 (1): 18.
- Кулаков В. И., Прилепская В. Н. Генитальные инфекции как фактор канцерогенеза шейки матки. В кн. Современные технологии в диагностике и лечении гинекологических заболеваний. М.: Пантори; 2004: 267-8.
- Липова Е. В., Радзинский В. Е. Бактериальный вагиноз: всегда дискуссии. Status Praesens. 2012; 7: 27-34.
- Радзинский В. Е., Ордиянц И. М. Двухэтапная терапия вагинальных инфекций. М.: Редакция журнала Status Praesens; 2012.
- Радзинский В. Е., Хамошина М. Б., Календжян А. С. и др. Эффективная коррекция нарушений биоценоза влагалища вне и во время беременности: почему это важно и что нового? Доктор.Ру. 2010; 7 (58)1: 20-6.
- ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Vaginitis Vaginitis. ACOG Practice Bulletin N72. American College of Obstetricians and gynecologist.Obstet Gynecol. 2006; 107: 1195-206.
- Joesoef M., Schmid G. Bacterial vaginosis. In: Clinical evidence. London: BMJ Publishing Group; 2001.
- Swidsinski A., Mendling W., Loening-Baucke V. et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am. J. Obstet. Gynecol. 2008; 198: 97.e1.